P01CA272239

Genetic variation in cancer risk and outcomes in African Americans - project summary/abstract—overall program genetic testing for both germline and somatic mutations has improved our understanding of the basic biology of carcinogenesis, identified high-risk populations for targeted prevention and screening, identified targets for new treatment strategies, and has led to some of the most significant inroads in reducing cancer burden.

Yet, there is still much to learn about the role of inherited genetic susceptibility and cancer, and the significant barriers to accessing genetic counseling and testing services, particularly in under-represented populations. We have assembled one of the largest populations of African American cancer survivors to date to study genetic susceptibility in this population.

The Detroit Research on Cancer Survivors (ROCS) (U01CA199240) cohort includes participants considered to be at particularly high-risk due to family history of cancer, age at diagnosis or a diagnosis of a second primary cancer, and the infrastructure will be used to expand participation. The program includes three projects and two cores with an overall goal of improving the identification and clinical management of hereditary and multiple primary cancers in African Americans, who are currently underrepresented in genetic research.

To do this we will: 1) use bioinformatic analyses, family structure, gene expression, and somatic alterations to identify African American cancer survivors most likely to harbor high-penetrance genetic variants currently classified as pathogenic or having uncertain significance; 2) characterize the spectrum of germline genetic variation in African Americans with multiple primary cancers in relation to known pathogenic mutations, site-specific polygenic risk scores (PRS), and largely modifiable non-genetic risk factors; and 3) develop an online, culturally adapted educational intervention to increase access to genetic counseling information among medically underserved African Americans and uptake of risk-appropriate genetic testing among those at increased risk so that we are poised to translate novel genetic discoveries into clinical practice.

Wayne State University

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Detroit, Michigan 48201 United States

Single Zip Code

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) (PAR-20-077)

Amendment Since initial award the total obligations have increased 97% from $1,919,811 to $3,779,932.